



COLORADO
 Department of Health Care
 Policy & Financing

DUR BOARD MEETING AGENDA

May 11, 2021

1:00 p.m. - 5:00 p.m. Open Session

Zoom Link will be posted at
<https://www.colorado.gov/pacific/hcpf/drug-utilization-review-board>
 prior to the meeting

Health First Colorado, Colorado Medicaid Drug Utilization Review Board

DUR Board Members	CO-DUR Team
Alison Shmerling, MD, MPH (Vice Chair)	Jeffrey Taylor, PharmD (HCPF)
Miroslav Anguelov, PharmD	Julia Rawlings, PharmD (CO DUR)
Todd Brubaker, DO	Robert L Page II, PharmD, MSPH (CO DUR)
Liza Wilson Claus, PharmD	Gina Moore, PharmD, MBA (CO DUR)
Brian Jackson, MD, MA	Heather Anderson, PhD (CO DUR)
Shilpa Klocke, PharmD	Garth Wright, MPH (CO DUR)
Lyle Laird, PharmD	Vanessa Patterson, MPH (CO DUR)
Patricia Lanus, BSPHarm, MHA	
Scott VanEyck, MD	

1. Call to Order
2. Roll Call / Introductions
3. Virtual Meeting Information and General Announcements
4. Colorado Department of Health Care Policy and Financing Updates
5. Election of Board Chair
6. Final Approval of Minutes from the March 23, 2021 Meeting (Physician Administered Drugs)
7. Reading of Rules for Public Testimony and Disclosure of Conflicts of Interest
 - Agenda items must be approved in advance, including requests to present information. Please contact the DUR Pharmacist, Jeff Taylor, at jeffrey.taylor@state.co.us with questions.
 - Anyone wishing to provide testimony must contact the DUR Pharmacist at least 24 hours before the meeting.

Our mission is to improve health care equity, access and outcomes for the people we serve while saving Coloradans money on health care and driving value for Colorado.

<https://hcpf.colorado.gov>





COLORADO

Department of Health Care Policy & Financing

8. Clinical Updates and General Orders

- Retrospective DUR Reports
- Quarterly Module Summaries
- FDA New Product & Safety Updates
- Quarterly Drug Utilization Reports

9. New Business (open for public testimony and Board review)

Proposed Criteria for PDL Drug Classes Scheduled for Review:

- Non-Opioid Analgesics
- Opioids, Short-Acting
- Fentanyl Preparations
- Opioids, Long-Acting
- Angiotensin modulators and Angiotensin modulator combinations
 - ACEIs, ACEI Combinations
 - ARBs, ARB Combinations
 - Renin Inhibitors & Combinations
- Acne Agents, Topical
- Acne Agents, Oral Isotretinoids
- Antineoplastics, Topical
- Rosacea Agents
- Phosphate Binders
- Respiratory Inhalants
 - Inhaled Anticholinergics & Anticholinergic Combinations
 - Inhaled Beta2 Agonists (short-acting)
 - Inhaled Beta2 Agonists (long-acting)
 - Inhaled Corticosteroids and Combinations
 - Phosphodiesterase Inhibitors (PDEIs)

Mass review drug classes*:

- Tetracyclines
- Skeletal Muscle Relaxants
- Topical Immunomodulators
- Androgenic Agents - Topicals, Injectables, Orals
- Antihistamines, Newer Generation & Combinations
- Benign Prostatic Hypertrophy (BPH) Agents

** Proposed criteria for drug classes designated for mass review will not be read aloud at the time of DUR Board review, as there are no proposed changes to criteria currently implemented for these designated classes. The DUR Board may determine if designated mass review drug classes will undergo full review based on board vote.*

Our mission is to improve health care equity, access and outcomes for the people we serve while saving Coloradans money on health care and driving value for Colorado.

<https://hcpf.colorado.gov>





COLORADO

Department of Health Care Policy & Financing

10. Proposed ProDUR and Prior Authorization Criteria for Other Selected Products

- UPLIZNA (inebilizumab)
- VILTEPSO (viltolarsen)
- HEMADY (dexamethasone)
- MYCAPSSA (octreotide DR)
- AMONDYS 45 (casimersen)
- BRONCHITOL (mannitol)
- GIMOTI (metoclopramide)
- Pharmacy Claims System Edit for Concomitant Opioid and Oral MAT Buprenorphine-Containing Products

11. Adjournment

Reasonable accommodations will be provided upon request for persons with disabilities. Please notify the Board Coordinator at jeffrey.taylor@state.co.us or the 504/ADA Coordinator hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

Next meeting date
August 10, 2021
1:00 pm to 5:00 pm

